Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
•
Liver and Pancreas Tumors
•
Hepatocellular Carcinoma
•
Gastroenterology
•
Journal Club ft. NEJM publications
•
General Hepatology
Are there any biomarkers that might indicate who might be responders to atezolizumab/bevacizumab for HCC?
ex. VEGFR2 expression, inflammatory signature, PDL1, etc.
Answer from: Medical Oncologist at Academic Institution
Not at this time. Some preliminary studies are being done as ad hoc at this point and was not pre specified before the IMbrave study launching
Comments
Medical Oncologist at University of Texas MD Anderson Cancer Center
Further studies are required for the value of PDL-...
3713
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
At this point nothing simple. There was some data presented at AACR 2020 from the single arm study but it looked at signatures. There were interesting findings but not ready for clinical practice
Sign in or Register to read more
8708
8714
Related Questions
How would active Crohn's on Adalimumab affect the adjuvant management of a T2aN0M0 gallbladder cancer?
What is your approach to liver transplantation candidacy in those with decompensated cirrhosis who have been treated for a solid-organ malignancy, such as oral SCC?
Would you rechallenge with cabozantinib in a patient with HCC after the development of a 6 mm gastrohepatic fistula without perforation or communication with the peritoneal cavity?
How would you approach the management of a patient with stage IIIA lung adenocarcinoma and multifocal hepatocellular carcinoma with Child-Pugh A cirrhosis?
What are your top takeaways in GI Cancers from ESMO 2024?
What are your top takeaways from ASCO GI 2025?
In a patient with amyloidosis and abnormal liver function but child Pugh A, would you still proceed with SABR for a liver metastasis?
Would you recommend radiation or chemoradiation in a patient with cholangiocarcinoma s/p surgery and adjuvant treatment with single hepatic metastasis 3 years later?
What systemic therapy and dose adjustments would you implement for patients with pancreas cancer and cirrhosis with pancytopenia?
Would you offer chemoRT to a colon cancer case with a resected polyp with positive margins if the patient wishes to avoid surgery?
Further studies are required for the value of PDL-...